Skip to main content
. Author manuscript; available in PMC: 2023 Mar 17.
Published in final edited form as: Life Sci. 2021 Oct 31;287:120114. doi: 10.1016/j.lfs.2021.120114

Figure 2. IRAK4i can counteract TLR7-potentiated immunometabolism in RA FLS.

Figure 2.

RA FLS were pretreated with IRAK4i (1μM) o/n before R837 (1μg/ml) stimulation for 6h and quantification of IRF1, IRF5 or IRF7 (A), metabolic intermediates including GLUT1, HIF1α, cMYC, LDHA, CARKL (B-C) or oxidative enzymes such as ACO2, OGDH, SDH2, MDH2 and FH (G) by realtime RT-PCR, n=4. Conditioned media were obtained from RA FLS untreated (PBS) or pretreated with IRAK4i (1μM) before R837 (1μg/ml) stimulation for 24h and quantification of Lactate (D) Citrate (E) and Succinate (F) by colorimetric assay, n=4. The data are shown as mean ± SEM, * represents p<0.05, ** denotes p<0.01.